JP2012533299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533299A5 JP2012533299A5 JP2012520638A JP2012520638A JP2012533299A5 JP 2012533299 A5 JP2012533299 A5 JP 2012533299A5 JP 2012520638 A JP2012520638 A JP 2012520638A JP 2012520638 A JP2012520638 A JP 2012520638A JP 2012533299 A5 JP2012533299 A5 JP 2012533299A5
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- promoter
- nucleic acid
- acid sequence
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22568709P | 2009-07-15 | 2009-07-15 | |
| US61/225,687 | 2009-07-15 | ||
| US28759909P | 2009-12-17 | 2009-12-17 | |
| US61/287,599 | 2009-12-17 | ||
| PCT/US2010/036247 WO2011008348A2 (en) | 2009-07-15 | 2010-05-26 | Dual vector for inhibition of human immunodeficiency virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015163281A Division JP6247259B2 (ja) | 2009-07-15 | 2015-08-21 | ヒト免疫不全ウイルス阻害のための二重ベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533299A JP2012533299A (ja) | 2012-12-27 |
| JP2012533299A5 true JP2012533299A5 (enExample) | 2013-07-11 |
| JP5828838B2 JP5828838B2 (ja) | 2015-12-09 |
Family
ID=42797105
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520638A Expired - Fee Related JP5828838B2 (ja) | 2009-07-15 | 2010-05-26 | ヒト免疫不全ウイルス阻害のための二重ベクター |
| JP2015163281A Expired - Fee Related JP6247259B2 (ja) | 2009-07-15 | 2015-08-21 | ヒト免疫不全ウイルス阻害のための二重ベクター |
| JP2017220978A Expired - Fee Related JP6529141B2 (ja) | 2009-07-15 | 2017-11-16 | ヒト免疫不全ウイルス阻害のための二重ベクター |
| JP2019089588A Expired - Fee Related JP6840189B2 (ja) | 2009-07-15 | 2019-05-10 | ヒト免疫不全ウイルス阻害のための二重ベクター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015163281A Expired - Fee Related JP6247259B2 (ja) | 2009-07-15 | 2015-08-21 | ヒト免疫不全ウイルス阻害のための二重ベクター |
| JP2017220978A Expired - Fee Related JP6529141B2 (ja) | 2009-07-15 | 2017-11-16 | ヒト免疫不全ウイルス阻害のための二重ベクター |
| JP2019089588A Expired - Fee Related JP6840189B2 (ja) | 2009-07-15 | 2019-05-10 | ヒト免疫不全ウイルス阻害のための二重ベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20120201794A1 (enExample) |
| EP (4) | EP3659435A1 (enExample) |
| JP (4) | JP5828838B2 (enExample) |
| AU (1) | AU2010274031B2 (enExample) |
| CA (1) | CA2767972A1 (enExample) |
| DK (2) | DK3329772T3 (enExample) |
| ES (3) | ES2657737T3 (enExample) |
| RU (2) | RU2562868C2 (enExample) |
| WO (1) | WO2011008348A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8909195D0 (en) | 1989-04-22 | 1989-09-13 | Cambridge Consultants | Scoring system |
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| GB201012410D0 (en) * | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
| CN103841982A (zh) * | 2011-06-29 | 2014-06-04 | 罗尼路发展有限公司 | Hiv感染的预防和治疗 |
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| EP3027755B1 (en) * | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| WO2016014837A1 (en) * | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
| EP4494699A3 (en) | 2014-10-03 | 2025-04-30 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| PL3294893T3 (pl) | 2015-05-13 | 2024-04-29 | Csl Behring Gene Therapy, Inc. | Bioprodukcja wektorów lentiwirusowych |
| HK1247963A1 (zh) * | 2015-05-18 | 2018-10-05 | Csl贝林基因治疗股份有限公司 | 用於hiv的治疗的基因疗法及其用途 |
| DK3283658T3 (da) | 2015-05-18 | 2020-05-18 | Calimmune Inc | Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| CN116064678A (zh) | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| WO2017139065A1 (en) * | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2017156311A2 (en) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| CN105861559B (zh) * | 2016-04-11 | 2018-05-01 | 苏州奥特铭医药科技有限公司 | 一种能直接反应i型干扰素应答的慢病毒载体及其制备方法与应用 |
| KR102427379B1 (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT |
| CN106086075B (zh) * | 2016-06-23 | 2019-08-06 | 福建医科大学 | CXCR4RNAi慢病毒载体的构建方法 |
| AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| JP7260170B2 (ja) * | 2017-01-09 | 2023-04-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 事前の免疫化ステップのないｈｉｖ免疫療法 |
| RU2019126483A (ru) | 2017-01-23 | 2021-02-24 | Ридженерон Фармасьютикалз, Инк. | Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| KR20190139869A (ko) | 2017-04-11 | 2019-12-18 | 리제너론 파마슈티칼스 인코포레이티드 | 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정 |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| JP2020524996A (ja) | 2017-06-16 | 2020-08-27 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| CN111164211B (zh) | 2017-07-18 | 2024-08-02 | 杰特贝林基因治疗股份有限公司 | 用于治疗β-血红蛋白病的组合物和方法 |
| AU2018348195B2 (en) | 2017-10-11 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| EP3697908A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| IL274632B2 (en) * | 2017-11-15 | 2024-12-01 | Weird Science Llc | Methods and compositions for non-myeloablative bone marrow reconstitution |
| AU2019239971B2 (en) | 2018-03-21 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof |
| CA3106403A1 (en) | 2018-07-15 | 2020-01-23 | Enochian BioPharma, Inc. | Methods and compositions using recombinant dendritic cells for cancer therapy |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| AU2022212090A1 (en) * | 2021-01-28 | 2023-07-06 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| RU2768032C1 (ru) * | 2021-09-02 | 2022-03-23 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Генетическая конструкция для экспрессии генов mNG_CD4-CXCR4, рекомбинантная плазмида rVSV_mNG_CD4-CXCR4 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CXCR4, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp 41 ВИЧ-1 тропности X4 |
| RU2769125C1 (ru) * | 2021-09-02 | 2022-03-28 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Генетическая конструкция для экспрессии генов mNG_CD4-CCR5, рекомбинантная плазмида rVSV_mNG_CD4-CCR5 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CCR5, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp41 ВИЧ-1 тропности R5 |
| CA3259099A1 (en) * | 2022-06-15 | 2023-12-21 | Cedars-Sinai Medical Center | Non-coding RNA agents (BCYRN1 and their derivatives) for treating immune disorders |
| WO2026039311A1 (en) * | 2024-08-10 | 2026-02-19 | Vectorgen | Lentiviral vector for treating human immunodeficiency virus infection |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
| US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US7737124B2 (en) * | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| RU2324738C2 (ru) * | 2006-06-16 | 2008-05-20 | Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) | ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ НА ОСНОВЕ ВЕКТОРНОЙ ПЛАЗМИДЫ pEGFP-N1, ПРОДУЦИРУЮЩАЯ siPHK-ИНГИБИТОРЫ РЕПРОДУКЦИИ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА 1 ТИПА (ЕЕ ВАРИАНТЫ) |
| CN101841399B (zh) * | 2009-03-16 | 2013-08-07 | 上海贝尔股份有限公司 | 多基站协作接收网络中实现同步上行harq进程的方法和装置 |
| RS53257B2 (sr) * | 2009-07-24 | 2018-06-29 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa |
-
2010
- 2010-05-26 ES ES15166660.9T patent/ES2657737T3/es active Active
- 2010-05-26 AU AU2010274031A patent/AU2010274031B2/en not_active Ceased
- 2010-05-26 JP JP2012520638A patent/JP5828838B2/ja not_active Expired - Fee Related
- 2010-05-26 WO PCT/US2010/036247 patent/WO2011008348A2/en not_active Ceased
- 2010-05-26 RU RU2012105281/10A patent/RU2562868C2/ru active
- 2010-05-26 RU RU2015133046A patent/RU2015133046A/ru not_active Application Discontinuation
- 2010-05-26 US US13/384,206 patent/US20120201794A1/en not_active Abandoned
- 2010-05-26 CA CA2767972A patent/CA2767972A1/en not_active Abandoned
- 2010-05-26 EP EP19198486.3A patent/EP3659435A1/en not_active Withdrawn
- 2010-05-26 DK DK17197440.5T patent/DK3329772T3/da active
- 2010-05-26 EP EP15166660.9A patent/EP2949208B1/en not_active Not-in-force
- 2010-05-26 DK DK15166660.9T patent/DK2949208T3/en active
- 2010-05-26 EP EP10720980.1A patent/EP2453735B1/en not_active Not-in-force
- 2010-05-26 ES ES10720980.1T patent/ES2546663T3/es active Active
- 2010-05-26 ES ES17197440T patent/ES2770627T3/es active Active
- 2010-05-26 EP EP17197440.5A patent/EP3329772B1/en active Active
-
2015
- 2015-08-21 JP JP2015163281A patent/JP6247259B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-09 US US15/150,373 patent/US20160243169A1/en not_active Abandoned
-
2017
- 2017-11-16 JP JP2017220978A patent/JP6529141B2/ja not_active Expired - Fee Related
-
2019
- 2019-05-10 JP JP2019089588A patent/JP6840189B2/ja not_active Expired - Fee Related
-
2021
- 2021-07-07 US US17/368,947 patent/US20220016176A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533299A5 (enExample) | ||
| RU2012105281A (ru) | Двойной вектор для подавления вируса иммунодефицита человека | |
| Mohamed et al. | Targeting CCR5 as a component of an HIV-1 therapeutic strategy | |
| AU2014296059B2 (en) | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors | |
| JP2023071897A (ja) | Ｈｉｖ感染のｒｎａガイド処置のための方法および組成物 | |
| Bobbin et al. | RNA interference approaches for treatment of HIV-1 infection | |
| EP3407918A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| US20210032627A1 (en) | Gene therapeutic for the treatment of hiv and uses thereof | |
| TW201602349A (zh) | 抗ｈｉｖ幹細胞及其用途 | |
| JP2018518196A5 (enExample) | ||
| Riley et al. | Cell-mediated immunity to target the persistent human immunodeficiency virus reservoir | |
| CN115720520A (zh) | 用于预防和/或治疗哺乳动物疾病的组合物和方法 | |
| Fanning et al. | Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen | |
| Khalid et al. | Stem cell therapy and its significance in HIV infection | |
| US20200061117A1 (en) | Protective Chimeric Antigen Receptor Stem Cell Gene Therapy for Viral Infection | |
| Lori et al. | Gene therapy approaches to HIV infection | |
| AU2015213417B2 (en) | Dual vector for inhibition of human immunodeficiency virus | |
| Engel et al. | Gene therapy for inborn and acquired immune deficiency disorders | |
| Re et al. | Chimeric Antigen Receptor-Modified Immune Cells for Eradication of HIV Reservoirs | |
| Sasson et al. | Site‐specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV‐1? | |
| CN118103076A (zh) | 可用于疾病治疗的慢病毒载体 | |
| Matamoros | Inhibition of CCR5 and CXCR4 prevents HIV infection | |
| JPH1118779A (ja) | 新規核酸及びそのエイズ発症抑制剤としての用途 | |
| HK1221488B (en) | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors | |
| TW200838873A (en) | Inhibition of HIV replication and expression of p24 with eIF-5A |